Your browser is no longer supported. Please, upgrade your browser.
Settings
ITRM [NASD]
Iterum Therapeutics plc
Index- P/E- EPS (ttm)-2.73 Insider Own0.30% Shs Outstand176.48M Perf Week-10.48%
Market Cap192.40M Forward P/E- EPS next Y-0.36 Insider Trans-97.56% Shs Float175.81M Perf Month-28.85%
Income-52.00M PEG- EPS next Q-0.07 Inst Own9.00% Short Float2.58% Perf Quarter-25.50%
Sales- P/S- EPS this Y69.50% Inst Trans-12.81% Short Ratio0.19 Perf Half Y141.25%
Book/sh-1.13 P/B- EPS next Y-5.90% ROA-156.30% Target Price- Perf Year-69.34%
Cash/sh0.10 P/C11.38 EPS next 5Y- ROE105.60% 52W Range0.45 - 6.02 Perf YTD12.23%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-81.56% Beta-
Dividend %- Quick Ratio0.50 Sales past 5Y- Gross Margin- 52W Low146.12% ATR0.12
Employees7 Current Ratio0.50 Sales Q/Q- Oper. Margin- RSI (14)40.42 Volatility8.07% 10.06%
OptionableNo Debt/Eq- EPS Q/Q84.30% Profit Margin- Rel Volume0.30 Prev Close1.18
ShortableYes LT Debt/Eq- EarningsMar 12 BMO Payout- Avg Volume24.35M Price1.11
Recom3.00 SMA20-8.87% SMA50-22.02% SMA2001.44% Volume7,256,769 Change-5.93%
Mar-15-21Upgrade H.C. Wainwright Neutral → Buy $2.50
Jun-02-20Downgrade RBC Capital Mkts Outperform → Sector Perform $7 → $2
Jan-21-20Downgrade Gabelli & Co Buy → Sell
Dec-11-19Downgrade SVB Leerink Outperform → Mkt Perform
Jun-21-19Initiated H.C. Wainwright Buy $17
Apr-06-21 08:30AM  
Mar-16-21 07:30AM  
Mar-12-21 07:00AM  
Mar-05-21 05:30PM  
Feb-19-21 05:30PM  
Feb-17-21 10:04AM  
Feb-10-21 06:40PM  
06:13AM  
Feb-09-21 11:58PM  
Feb-04-21 02:43AM  
Feb-03-21 11:35PM  
05:51PM  
Feb-01-21 07:00AM  
Jan-25-21 07:00AM  
Jan-06-21 05:00PM  
Dec-23-20 07:00AM  
Dec-21-20 05:00PM  
Dec-07-20 08:00AM  
Nov-30-20 09:15AM  
Nov-16-20 06:45AM  
Oct-23-20 12:02AM  
Oct-19-20 07:10PM  
06:00PM  
Oct-01-20 05:15PM  
Sep-30-20 07:45AM  
07:00AM  
Sep-08-20 04:30PM  
Sep-02-20 07:00AM  
Aug-31-20 08:00PM  
Aug-11-20 08:00AM  
Aug-06-20 06:45AM  
Jul-13-20 04:05PM  
Jun-30-20 09:12AM  
Jun-29-20 07:30AM  
Jun-15-20 04:30PM  
Jun-03-20 03:45PM  
09:50AM  
Jun-02-20 09:42AM  
Jun-01-20 08:30AM  
May-14-20 09:31AM  
06:45AM  
Apr-09-20 04:05PM  
Mar-31-20 07:00AM  
Mar-12-20 06:45AM  
Feb-19-20 07:30AM  
Jan-17-20 06:15AM  
Jan-03-20 03:15PM  
Dec-26-19 05:00PM  
Dec-12-19 09:42AM  
Dec-11-19 07:21AM  
Dec-10-19 04:10PM  
Nov-30-19 10:18AM  
Nov-18-19 07:30AM  
Nov-12-19 07:05PM  
04:30PM  
Nov-08-19 01:01PM  
Nov-06-19 10:30AM  
Oct-01-19 10:07AM  
Sep-27-19 04:30PM  
Sep-09-19 03:24PM  
Aug-14-19 08:15AM  
07:00AM  
Aug-06-19 10:30AM  
Aug-01-19 07:30AM  
Jul-10-19 12:13PM  
Jul-01-19 09:13AM  
Jun-21-19 07:30AM  
Jun-20-19 11:13AM  
Jun-07-19 09:27AM  
May-14-19 07:00AM  
Apr-12-19 10:08AM  
Apr-11-19 07:30AM  
Mar-28-19 09:00AM  
08:27AM  
Mar-25-19 07:00AM  
Mar-19-19 07:00AM  
Feb-21-19 10:15AM  
Feb-19-19 07:30AM  
Jan-17-19 10:00AM  
Dec-20-18 12:36PM  
Nov-14-18 07:15AM  
Nov-05-18 04:05PM  
Oct-05-18 08:00AM  
Sep-25-18 04:05PM  
Sep-20-18 08:00AM  
Sep-18-18 08:00AM  
Aug-14-18 07:30AM  
Aug-09-18 04:05PM  
Jun-06-18 10:08AM  
08:00AM  
May-25-18 12:51AM  
May-24-18 08:15PM  
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DENNER ALEXANDER J10% OwnerFeb 12Sale2.2710,619,94924,107,2840Feb 12 08:22 PM
DENNER ALEXANDER J10% OwnerFeb 11Sale2.5910,000,00025,900,00010,619,949Feb 12 08:22 PM
Fishman Corey N.President & CEOJan 26Sale1.7385,445147,820322,008Jan 27 07:35 PM
Dunne Michael W.DirectorJan 26Sale1.7333,14357,337256,355Jan 27 07:32 PM
Matthews Judith M.Chief Financial OfficerJan 26Sale1.7333,86858,59228,632Jan 27 07:32 PM
Matthews Judith M.Chief Financial OfficerSep 30Sale1.6456,13092,0530Oct 02 09:00 PM
Sofinnova Venture Partners IX,10% OwnerJun 02Sale1.61400,000642,9601,226,514Jun 03 08:20 PM
Sofinnova Venture Partners IX,10% OwnerJun 01Sale1.69100,000169,1201,626,514Jun 03 08:20 PM